Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures

@article{Besag2016ClinicalEO,
  title={Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures},
  author={Frank M. C. Besag and Philip N Patsalos},
  journal={Neuropsychiatric Disease and Treatment},
  year={2016},
  volume={12},
  pages={1215 - 1220}
}
Background and purpose Perampanel, a selective noncompetitive antagonist at the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is highly effective in a wide range of experimental models. Although initially licensed as adjunctive therapy for partial seizures with or without secondary generalization in patients aged 12 years or older, the US Food and Drug Administration has recently approved its use in the treatment of primary generalized tonic–clonic seizures (PGTCS). This… 

Figures from this paper

Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations

Results of an objective seizure response in 9 (75%) out of 12 patients treated by PER in DRE may be interpreted as a surrogate-marker of tumor response secondary to AMPA blockade, advancing confirmation by MR imaging.

Safety aspects of antiepileptic drugs—a population-based study of adverse effects relative to changes in utilisation

This study demonstrates that most adverse effects reported concerned AEDs increasingly used in non-epilepsy indications: neuropathic pain (pregabalin, gabapentin, carbamazepine) and psychiatry (lamotrigine, valproate, carbazepine).

ПРИМЕНЕНИЕ ПЕРАМПАНЕЛА В ЛЕЧЕНИИ ЭПИЛЕПСИИ: ОБЗОР ЛИТЕРАТУРЫ И ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ

It is concluded that perampanel is a promising drug in treating epilepsy (even in epilepsies resistant to many other AEDs) with favorable indicators of tolerability.

High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology

An in vivo drug screening strategy that combines high-throughput technology to generate large-scale brain activity maps to be used with machine learning to predict the therapeutic potential of clinically relevant drug leads is described.

Features of psychological reactions induced by perampanel: A case report

Perampanel, an anticonvulsant, might induce psychological reactions and be used in clinical practice to treat central nervous system disorders.

Repurposed Edaravone, Metformin, and Perampanel as a Potential Treatment for Hypoxia–Ischemia Encephalopathy: An In Vitro Study

Among these repurposed drugs, edaravone emerged as the most efficient in the attenuation of events induced by hypoxia–ischemia, and the safest, since it did not exhibit significant cytotoxicity, even in high concentrations, and induced a decrease in ROS.

Safety aspects of antiepileptic drugs—a population-based study of adverse effects relative to changes in utilisation

It is demonstrated that most adverse effects reported concerned AEDs increasingly used in non-epilepsy indications: neuropathic pain (pregabalin, gabapentin, carbamazepine) and psychiatry and psychiatry (lamotrigine, valproate, carbazepine).

References

SHOWING 1-10 OF 27 REFERENCES

Adjunctive perampanel for refractory partial-onset seizures

This trial demonstrated that once-daily, adjunctive perampanel at doses of 8 or 12 mg improved seizure control in patients with uncontrolled partial-onset seizures.

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy

This study provides Class I evidence that adjunctive perampanel reduces PGTC seizure frequency, compared with placebo, in patients with drug-resistant PGTC seizures in IGE.

Clinical experience with perampanel: Focus on psychiatric adverse effects

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

Overall, perampanel has a favorable clinical pharmacology profile, which should aid its clinical use and can be used to advantage because dose titration can be faster and thus optimum therapeutic outcome can be achieved sooner.

Adverse effects and safety profile of perampanel: A review of pooled data

Overall, perampanel appears to be associated with a relatively low incidence of serious adverse effects, particularly at low doses, and the majority of TEAEs were mild or moderate in intensity.

Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences.

Perampanel seems to be effective also in children and adolescents with pharmaco-refractory epilepsies and tolerability was acceptable.

Randomized phase III study 306

This trial demonstrated that adjunctive perampanel effectively reduced seizure frequency and possessed a favorable tolerability profile in patients ≥12 years with partial-onset seizures (with or without secondary generalization), with a minimum effective dose of 4 mg/day.